Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Reata’s Skyclarys Approval Aided By Natural History And Delayed-Start Analyses

Mar 05 2023

• By Bridget Silverman

Frataxin — REDUCED EXPRESSION OF THE FRATAXIN MITOCHONDRIAL PROTEIN CAUSES FRIEDREICH'S ATAXIA. • Source: Shutterstock

Related Content

Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin

Feb 25 2022

RWE On The Runway: Trio Of Upcoming Approval Decisions Will Test US FDA’s Thinking On RWE For Efficacy

Sep 06 2022

Related Companies

Reata Pharmaceuticals, Inc.

Additional Topics

United States Rare Diseases Real-World Evidence Approvals Drug Review Drug Approval Standards Regulation US FDA Performance Tracker Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.